Study for intrauterine transplantation with autologous platelet-rich plasma combined with of mesenchymal blood-derived stem cells for thin endometrium and Asherman’s syndrome

Basic and clinical study for intrauterine transplantation with autologous platelet-rich plasma combined with of mesenchymal blood-derived stem cells for endometrial injury

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000029267

Enrollment

Unknown

Registered

2020-01-19

Start date

2020-01-30

Completion date

Unknown

Last updated

2020-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thin endometrium and Asherman’s syndrome

Interventions

Asherman’s syndrome control:Intrauterine adhesion separation

Asherman’s syndrome with MenSCs transplantation:MenSCs transplantation after intrauterine adhesion separation

Asherman’s syndrome with PRP transplantation:PRP perfusion after intrauterine adhesion separation

Asherman’s syndrome with MenSCs/PRP transplantation:MenSCs/PRP transplantation after intrauterine adhesion separation

Thin endometrium control:Hormonal regulation alone

Thin endometrium with MenSCs transplantation:MenSCs transplantation after hormonal regulation

Thin endometrium with MenSCs transplantation:PRP perfusion after hormonal regulation

Thin endometrium with MenSCs/PRP transplantation:MenSCs/PRP transplantation after hormonal regulation

Thin endometrium MenSCs / PRP self-assembling peptide implantation group:MenSCs / PRP self-assembling peptide implantation after hormonal regulation

Asherman’s syndrome with MenSCs / PRP self-assembling peptide implantation group:MenSCs / PRP self-assembling peptide implantation after intrauterine adhesion separation

Eligibility

Sex/Gender

Female

Age

20 Years to 40 Years

Inclusion criteria

Inclusion criteria: Patients with intrauterine adhesions: (1) Aged between 20 and 40 years; (2) Meet the diagnostic criteria for hysteroscopy and be confirmed by hysteroscopy; (3) Serum hormone levels are within the normal range; (4) No congenital or acquired uterine malformations; Patients with thin endometrium: (1) Aged between 20 and 40 years; (2) the factor endometrium is thin (<7 mm) in the hormone replacement (HRT) cycle to cancel embryo transfer; (3) No congenital or acquired uterine deformity; (4) Transplant 1 blastocyst or 2 blastomeres, at least one of which is a high quality embryo.

Exclusion criteria

Exclusion criteria: Exclusion criteria for patients with intrauterine adhesions: patients with uterine fibroids, endometriosis, thin endometrium and other organ abnormalities. Exclusion criteria for thin endometrial patients: Patients with other known causes of implantation failure, such as poor embryo quality, congenital uterine abnormalities, or Asherman syndrome.

Design outcomes

Primary

Measure	Time frame
Adhesion score;Endometrial thickness;Clinical pregnancy rate;	—

Countries

China

Contacts

Public ContactBin Wu

Ji'nan Central Hospital Affiliated to Shandong University

wb0538@163.com+86 18668902156

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026